INS and type 2 diabetes mellitus: The most commonly reported adverse events (AEs) were nausea, vomiting, anorexia or reduced appetite, and severe hypoglycemia in studies in patients with type 1 diabetes (when the insulin dose was not simultaneously reduced), and nausea and mild to moderate hypoglycemia in studies in patients with type 2 diabetes [9–12, 15, 16].